rethinkTHC Search
Menu
Study breakdown

CBD shows potential against stomach and colorectal cancers through multiple pathways

Systematic ReviewPreliminary evidence
The takeaway

A systematic review found CBD targets gastrointestinal cancers through apoptosis, cell cycle regulation, anti-angiogenesis, and inflammation reduction, with potential to enhance conventional therapies and overcome treatment resistance.

GI oncology researchers, scientists studying cannabinoid anti-cancer mechanisms, and clinicians following emerging treatments for colorectal and gastric cancers.

CBD targeted multiple resistance mechanisms in GI cancer models

What the researchers found

CBD modulated multiple molecular pathways relevant to GI cancers, including inducing apoptosis and cell cycle arrest, inhibiting new blood vessel formation, reducing inflammation, and potentially enhancing chemotherapy effectiveness and overcoming drug resistance.

Why it matters

Gastrointestinal cancers are among the most common and deadly cancers globally. CBD's multi-target approach and potential to overcome treatment resistance address key challenges in GI oncology.

The numbers in context

CBD mechanisms in GI cancers included: apoptosis induction, cell cycle arrest, angiogenesis inhibition, inflammation reduction, and chemosensitization. Focus on gastric and colorectal cancer models.

How the study worked

Systematic review examining preclinical and early clinical evidence on CBD in gastric and colorectal cancers, analyzing molecular pathways and therapeutic potential.

What this study cannot tell us

Primarily preclinical evidence. Translation from lab to clinic faces bioavailability, dosing, and regulatory challenges. CBD's GI side effects could complicate treatment of GI cancers specifically.

How to read the evidence

Systematic review of predominantly preclinical work. Provides mechanistic understanding but clinical translation remains speculative.

When this study was published

Published in 2025.

The bigger picture

Colorectal cancer treatment has improved but resistance remains a major hurdle. The cannabinoid system is expressed in the GI tract, making it a biologically plausible therapeutic target for cancers arising in these tissues.

Questions still open

  • Would oral CBD achieve sufficient concentrations at GI tumor sites? Could CBD's GI side effects be leveraged therapeutically rather than being a limitation?

Common questions

Could CBD help treat stomach or colon cancer?
Preclinical studies show CBD can kill GI cancer cells and may enhance chemotherapy. However, clinical evidence is lacking, and significant challenges remain in translating lab findings to patient treatment.
How does CBD fight GI cancers?
CBD was found to induce cancer cell death, stop cell division, inhibit blood vessel growth that feeds tumors, reduce inflammation, and potentially make cancer cells more sensitive to existing treatments.

Read the original research

Targeting Gastrointestinal Cancers with Cannabidiol: Mechanisms, Challenges, and Therapeutic Implications.

Medical oncology (Northwood, London, England), 42(7), 237

Citation

Esmaeli, Mojtaba; Dehghanpour Dehabadi, Maryam. (2025). Targeting Gastrointestinal Cancers with Cannabidiol: Mechanisms, Challenges, and Therapeutic Implications.. Medical oncology (Northwood, London, England), 42(7), 237. https://doi.org/10.1007/s12032-025-02790-6

Explore the wider topic